5EA Stock Chart & Stats
€20.69
€0.00(0.00%)
At close: 4:00 PM EDT
€20.69
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€16.69 - €23.15
Previous CloseN/A
Volume0.00
Average Volume (3M)40.00
Market Cap
€10.09B
Enterprise Value€15.84B
Total Cash (Recent Filing)€530.00M
Total Debt (Recent Filing)€3.92B
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Nov 06, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding499,621,830
10 Day Avg. Volume122
30 Day Avg. Volume40
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.72
Price to Sales (P/S)2.38
P/FCF Ratio39.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€28.04Price Target Upside35.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)1.02
Revenue Forecast (FY)€4.59B
Bulls Say, Bears Say
Bulls Say
Raised Revenue And Earnings OutlookThe raised outlook indicates that Elanco is seeing broad enough demand and execution to support higher expectations across revenue and adjusted earnings. Sustained organic growth, rather than acquisition contribution alone, can strengthen operating scale and provide a durable foundation for reinvestment over the next several quarters.
Strong Innovation AdoptionZenrelia’s clinic penetration, patient reach, and high reorder rate provide evidence of meaningful product-market adoption rather than only launch-stage interest. Continued uptake across 47 countries can expand Elanco’s recurring commercial base, support innovation revenue, and improve portfolio durability.
Positive Cash GenerationPositive free cash flow while reported net income remains negative demonstrates that Elanco is generating internal funding from its operating model. This supports debt service, product investment, and commercial launches, while giving management more flexibility to improve the balance sheet without relying solely on external capital.
Bears Say
Persistent Bottom-line LossesElanco’s revenue and gross margin improvements have not yet translated into consistent positive net earnings. Continued losses and negative returns on equity reduce the effectiveness of the capital base, constrain internally funded growth, and leave execution dependent on further margin improvement.
Leverage Remains MaterialBalance-sheet risk has improved, but leverage remains meaningful relative to the company’s current profitability. Debt obligations can limit financial flexibility and increase the importance of reliable cash generation, while reaching the lower long-term leverage target will require sustained execution and deleveraging.
Befrena Supply ConstraintsDemand exceeding expectations is encouraging, but the extended supply constraint prevents Elanco from fully converting early commercial interest into near-term revenue. The phased bioreactor scale-up may delay product availability, limit launch momentum, and defer the contribution of a potentially important new therapy.
5EA FAQ
What was Elanco Animal Health’s price range in the past 12 months?
Elanco Animal Health lowest stock price was €16.69 and its highest was €23.15 in the past 12 months.
What is Elanco Animal Health’s market cap?
Elanco Animal Health’s market cap is €10.09B.
When is Elanco Animal Health’s upcoming earnings report date?
Elanco Animal Health’s upcoming earnings report date is Nov 06, 2026 which is in 23 days.
How were Elanco Animal Health’s earnings last quarter?
Elanco Animal Health released its earnings results on Aug 05, 2026. The company reported €0.304 earnings per share for the quarter, beating the consensus estimate of €0.241 by €0.064.
Is Elanco Animal Health overvalued?
According to Wall Street analysts Elanco Animal Health’s price is currently Undervalued.
Does Elanco Animal Health pay dividends?
Elanco Animal Health does not currently pay dividends.
What is Elanco Animal Health’s EPS estimate?
Elanco Animal Health’s EPS estimate is 0.18.
How many shares outstanding does Elanco Animal Health have?
Elanco Animal Health has 499,621,830 shares outstanding.
What happened to Elanco Animal Health’s price movement after its last earnings report?
Elanco Animal Health reported an EPS of €0.304 in its last earnings report, beating expectations of €0.241. Following the earnings report the stock price went down -0.498%.
Which hedge fund is a major shareholder of Elanco Animal Health?
Currently, no hedge funds are holding shares in DE:5EA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elanco Animal Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€28.04 (35.54% Upside)
€28.04 (35.54% Upside)
Blogger Sentiment
Neutral
DE:5EA Sentiment 57%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth €480.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.17%
12-Months-Change
Fundamentals
Return on Equity
-3.02%
Trailing 12-Months
Asset Growth
-1.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Elanco Animal Health
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
5EA Company Deck
5EA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: strong top-line performance (8% organic growth, $1.368B revenue), robust innovation momentum (Zenrelia, Credelio Quattro, AdTab), margin expansion (adjusted gross margin +80 bps, adjusted EBITDA +21%, adjusted EPS +31%), raised full-year guidance, and improving leverage (target ~3.0x year-end). Near-term headwinds include inventory cost pressures, elevated inflation, continued operating expense investments (DTC/R&D) and some regional/timing softness in International Farm Animal. Supply constraints for Befrena and moderating comparisons for some Farm Animal products are acknowledged but framed as manageable. Overall, highlights materially outweigh the limited lowlights.View all DE:5EA earnings summaries5EA Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€28.04
▲(35.54% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month









